Hydroxyurea for treatment of sickle cell disease;Traitement de la drépanocytose par l'hydroxyurée

Hematologie

Volumn 8, Issue 1, 2002, Pages 28-34

  De Montalembert, Mariane ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Fetal hemoglobin; Hydroxyurea; Pain; Sickle cell diasease

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA;

ACUTE CHEST SYNDROME; BLOOD TRANSFUSION; CELL ADHESION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERANCE; ENDOTHELIUM; HEMOGLOBIN SYNTHESIS; HUMAN; LEUKOPENIA; LONG TERM CARE; PAIN; PATHOPHYSIOLOGY; REVIEW; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA;

EID: 0036205189     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
2. Multicenter study of hydroxyurea in sickle cell anemia. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia
3. Adhesive interactions of sickle erythrocytes with endothelium
4. Pathogenesis and treatement of sickle cell disease
5. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice
6. Prediction of adverse outcomes in children with sickle cell disease
7. Bases physiopathologiques moléculaires et cellulaires du traitement de la drépanocytose
8. Stimulation de la production d'hémoglobine foetale chez l'enfant drépanocytaire
9. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients
10. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease
11. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy
12. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea
13. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin
14. Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst
15. Effect of hydroxyurea on endothelial cells in culture
16. Fetal hemoglobin in sickle cell disease: Relationship to erythrocyte phosphatidylserine exposure and coagulation activity
17. Production of nitric oxyde metabolites in sickle cell patients after administration of hydroxyurea
18. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea
19. Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: The MSH at 7-8 years of follow-up
20. Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle cell/β-thalassemia
21. Cellular effects of hydroxyurea in Hb SC disease
22. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease
23. Azoospermia in a patient with sicle cell disease treated with hydroxyurea
24. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial
25. Five years of experience with hydroxyurea in children and young adults with sickle cell disease
26. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease
27. Follow-up of a cohort of 133 children affected with sickle cell disease treated with hydroxyurea
28. Safety of Hydroxyurea in children with sickle cell anemia: Result of the HUG-KIDS study, a phase I/II trial
29. Use of hydroxyurea in children aged 2 to 5 years with sickle cell disease
30. Effect o hydroxyurea on growth of the brain and other organs in infant mice
31. Acute leukemia; hydroxyurea and polycythemia vera: An analysis of risk from the Polycythemia vera Study Group
32. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease
33. Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia
34. Role of hydroxyurea in the occurrence of bladder cancer?
35. Hydroxyurea therapy in children severely affected with sickle cell disease
36. Hydroxyurea in children with sickle cell disease
37. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease
38. Single center experience of long term use of hydroxyurea-therapy for pediatric SCD patients: Interest of HU for patients with severe anemia
39. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease
40. 2-Deoxy-5-azacytidine and fetal hemoglobin induction in sickle cell anemia